Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2023 Nov 27;18(11):e0287665. doi: 10.1371/journal.pone.0287665

Leishmanicidal and healing effects of 3β,6β,16β-trihydroxy lup-20 (29)-ene isolated from Combretum leprosum on Leishmania braziliensis infection in vitro and in vivo

Aline Sombra Santos 1, Naya Lúcia de Castro Rodrigues 1, Francisco Rafael Marciano Fonseca 1,2, Nathalia Braga Fayão Oliveira 1, Bianca Oliveira Loucard 2, Fabíola Fernandes Heredia 1, Teresa Neuma Albuquerque Gomes Nogueira 1, Ticiana Monteiro Abreu 1, Hélcio Silva dos Santos 3, Edson Holanda Teixeira 4, Luzia Kalyne Almeida Moreira Leal 2, Regis Bernardo Brandim Gomes 5, Clarissa Romero Teixeira 5, Maria Jania Teixeira 1,*
Editor: Manas Ranjan Dikhit6
PMCID: PMC10681296  PMID: 38011211

Abstract

Treatment of cutaneous leishmaniasis depends on drugs that potentially cause serious side effects and resistance. Thus, topical therapies are attractive alternatives to the drugs currently used. 3β, 6β, 16β-trihydroxylup-20 (29)-ene is a lupane triterpene isolated from Combretum leprosum Mart. leaves (CLF-1), with reports of in vitro antileishmanial effect against L. amazonensis and to promote lesion healing in animal model. Herein, we evaluated the in vitro and in vivo antileishmanial and healing effects of CLF-1 against L. braziliensis. CLF-1 treatment showed low toxicity in macrophages and significantly reduced parasite load in vitro. CLF-1 induced higher IL-12 and TNF-α production and more discrete IL-4 and IL-10 production. For in vivo evaluation, a CLF-1 cream formulation was prepared to treat hamsters infected with L. braziliensis. CLF-1 treatment was able to reduce parasite load of the infected skin and lymph node more efficiently than the conventional treatment. Histopathological analysis indicated a strong inflammatory response accompanied by an important healing response. Data from this study indicate that topical CLF-1 treatment was effective and non-toxic in L. braziliensis infected hamsters suggesting its potential for further development as a future therapeutic intervention.

Introduction

Leishmaniasis are parasitic diseases typical of tropical and subtropical regions, present in 102 countries. In Brazil, studies report the occurrence of about 20,000 new cases of the disease per year [1].

The disease can manifest in visceral or tegumentary forms and the clinical spectrum depends on complex interactions, including parasite and host, such as Leishmania species and tropism, and the host immune status [2]. In Ceará, Brazil, cutaneous leishmaniasis (CL) has as main etiological agent L. braziliensis [3], a species capable of inducing localized cutaneous leishmaniasis, as well as mucocutaneous involvement with mucosal lesions of the oropharynx, and high morbidity [4].

The vertebrate host’s main defense against leishmaniasis is through cell-mediated immune response, demonstrated by lymphocyte proliferation and production of the inflammatory cytokines IFN-γ and TNF-α [5]. However, these cytokines also mediate tissue damage, high levels of IFN-γ and TNF-α have been associated with increased inflammatory reaction and development of skin ulcers and mucosal lesions [6]. In L. braziliensis infection in humans, it has been shown that the balance between IFN-γ and IL-10 is crucial for wound healing [7]. IL-10 has an anti-inflammatory effect, counteracting the inflammatory effect of IFN-γ and TNF-α [8, 9].

The first-choice treatment for leishmaniasis has been done for over 5 decades with pentavalent antimonial. The toxicity of these agents and the persistence of side effects, even after dose level modification and treatment duration, are the main reported drawbacks [10]. Alternative treatment, such as liposomal amphotericin B and pentamidine, also have several side effects and inconveniences, including the high cost [11, 12]. In addition, the development of current drug resistant Leishmania strains in recent years has made the disease increasingly difficult to treat [13].

In the absence of a vaccine, there is an urgent need for more effective drugs to replace or supplement commonly used drugs. Natural herbal products are potential valuable sources for new medicinal agents. Several classes of plant-extracted natural products have shown promising leishmanicidal potential in vitro and/or in vivo, such as flavonoids, coumarins, quinones, quinoline alkaloids and terpenes, among others [14]. Lupane triterpene, 3β,6β,16β-trihydroxilup-20(29)-ene, isolated from Combretum leprosum Mart. (CLF-1) exhibited leishmanicidal activity against L. amazonensis promastigotes and amastigotes in vitro [15, 16]. In addition, CLF-1 demonstrated healing effect in a murine skin wound model [17].

To contribute to these studies, we investigated the leishmanicidal, inflammatory and healing effects of CLF-1, a natural product of the triterpene class, isolated from the leaves of a Brazilian northeast plant, Combretum leprosum Mart., in vitro and in vivo against L. braziliensis infection. Additionally, a cream formulation of CLF-1 for topical treatment was prepared and tested resulting in enhanced lesion healing. The result of this work suggests that CLF-1 could be a safe, effective alternative treatment option for control of leishmaniasis.

Material and methods

Triterpene 3β,6β,16β-triidroxilup-20(29)-ene: CLF-1

Leaves of Combretum leprosum were collected in June 2009 at Salgado dos Machados district, located 15 km from the city of Sobral, Ceará, Brazil. The plant classification was performed by a plant taxonomist from Acaraú Valley State University (Sobral, Brazil). A specimen of this plant was deposited in Herbarium Francisco José de Abreu Matos (Sobral, Brazil), under N∘ 4573. As previously described, the 3β,6β,16β-trihydroxy lup-20(29)-ene (CLF-1) was obtained initially by extraction from fresh C. leprosum leaves with EtOH/H2O (v/v, 8:2) for 15 days, filtered and evaporated under reduced pressure. The extract was fractioned by liquid chromatography over silica gel to purify CLF-1 (Fig 1). For structural analysis infrared spectra were recorded using a Perkin-Elmer 1000 spectrophotometer and 1H and 13C NMR were recorded on a Bruker Avance DPX-500 [18]. For in vitro experiments, a stock solution of CLF-1 was prepared freshly prior to use, using dimethylsulfoxide (DMSO) as a solvent. The appropriate concentrations were obtained by diluting the stock solution in sterile distilled water, and the final concentration of DMSO in the incubation mixture never exceeded 0.1%. Control samples were always treated with the same amount of DMSO (0.1% v/v) as used in the corresponding experiments.

Fig 1. CLF-1 or 3β,6β,16β-trihydroxy lup-20(29)-ene chemical structure isolated from C. leprosum leaves alcoholic extract [16].

Fig 1

Open in a new tab

Parasites

Leishmania (Viannia) braziliensis strain (MCAN/BR/98/R619) was kindly provided by Prof. Dr. Maria Alda da Cruz from Oswaldo Cruz Foundation (FIOCRUZ-RJ) and were kept frozen at -80°C at the Parasitology Laboratory of the Federal University of Ceará. Parasites were cultured at 25°C in N.N.N. medium containing Schneider supplemented with 20% inactivated fetal bovine serum (SBF), 2% sterile human urine, 100 U/mL penicillin and 100 μg/mL streptomycin.

Animals

Female Syrian hamsters (Mesocricetus auratus), 6 to 8 weeks old, weighing around 80 to 90g, were obtained from the central animal facility of Pathology and Legal Medicine Department of Federal University of Ceará (DPML/UFC), maintained at 25°C, in an alternating light/dark cycle, with food and water ad libitum. The Animal Care and Utilization Committee from UFC approved all experimental procedures (Protocol no. 6490040418).

CLF-1 cream

A cream formulation containing 50 μg of CLF-1/15 mg base cream was used for in vivo treatment. The cream was formulated with cetearyl alcohol with Steareth-10 and -20 (5%), isopropyl palmitate (5%), butylated hydroxytoluene (BHT) (0.06%), propylparaben (0.06%), methylparaben (0.18%), glycerin (5%), disodium EDTA (0.12%), distilled water and 1% EDTA 2020 gel base (15%) in the Pharmacognosy and Pharmaceutical Technology Laboratory (Faculty of Pharmacy—UFC). As a control, the vehicle (1% EDT 2020 base gel) was used.

Effect of CLF-1 on promastigotes

Culture containing promastigote forms were centrifuged at 3.000 rpm for 15 minutes at 4°C, resuspended in Schneider medium, counted, and diluted in supplemented Schneider medium to obtain a concentration of 1x107 promastigotes/mL. Promastigotes were distributed in 48-well plates in a volume of 160 μL in each well and diluted CLF-1 was added at the respective concentrations of 5, 10, 25, 50 and 100 μg/mL. For control, 1% DMSO, Amphotericin B (16 μg/mL) and non-supplemented Schneider medium were used [19]. The plates were incubated for 24 and 48 hours at 25°C and the number of viable promastigotes was determined.

Cytotoxicity assay in macrophages

J774 macrophages were cultured in supplemented RPMI medium and maintained at 5% CO2, 95% humidity at 37°C. J774 macrophages (5 x 105 cells/mL) were incubated with CLF-1 (5, 10, 25, 50 and 100 μg/mL), DMSO 1% (CLF-1 vehicle), DMSO 10% (cytotoxic standard) and Amphotericin B in 96-well microplates. Cytotoxicity in J774 macrophages was evaluated after 24 and 48 h using the standard MTT colorimetric assay. For reading, each plate was shaken for 10 minutes, and absorbance was measured on a spectrophotometer with a wavelength of 570 nm.

Effect against intracellular amastigotes

J774 macrophages (1x106 macrophages/m) were distributed in 24-well flat-bottomed plates containing round glass coverslips (23 mm). For macrophage infection with L. braziliensis, parasites were added at a concentration of 1x107 parasites/mL. The infected macrophages were incubated for an additional 24 h and then CLF-1 (10, 25, 50 and 100 μg / mL), 1% DMSO, Glucantime® (4 mg/mL) and Interferon-γ (20 ng/mL) were added. Plates were incubated at 5% CO2 at 37°C and 95% humidity for 24 and 48 hours. After this time, the supernatants were removed from the wells and then stored at -20°C for further cytokine analysis. For parasitic load evaluation, coverslips were removed from each well and washed with saline, fixed, and stained with Giemsa and examined under optical microscope. Amastigotes were counted in 50 typical macrophages on each coverslip.

Evaluation of cytokine production

Production of IL-10, IL-4, IL-12 and TNF-α cytokines was determined by ELISA using supernatants obtained from culture of L. braziliensis-infected macrophages. Assays were performed according to the instructions of the ELISA kit manufacturer (BD Biosciences).

In vivo infection and treatment with CLF-1 cream

Stationary phase L. braziliensis promastigotes were inoculated into the right ear dermis of each animal, according to the groups, at a concentration of 1x107 in 20 μL of sterile saline [20]. Animals (n = 30) were randomly separated into 3 groups (10 animals each) and anesthetized with ketamine (80 mg/kg, i.p.) and xylazine (15 mg/Kg) before infection: 1. Group infected and treated with the cream vehicle (negative control); 2. Group infected and treated with Glucantime® (treatment control group, 100 mg/Kg, IM); 3. Group infected and treated with CLF-1 cream formulation (50 μg/ 15mg). Treatment began shortly after the onset of the ulcerated lesion 15 days after infection and was performed for 10 consecutive days. Glucantime® was administered intramuscularly (100 mg/kg, I.M., 80 μL in each animal), alternating between right and left thigh each day. The amount of cream containing or not CLF-1 was measured on a precision scale using a flat spatula containing the cream. The ear lesion was exposed with the help of tweezers and the ointment was applied over the lesion. Lesion thickness of the right and left ears (control) was measured for 45 days with a circular caliper (Mitutoyo, Japan). Lesion thickness was assessed as the difference between the inoculated ear and the uninoculated collateral ear.

Parasitic load evaluation

Animals were euthanized with an i.p. injection of ketamine (600 mg/kg) and xylazine (30 mg/kg) after 10 days of treatment, 25 days after infection. Infected ears and retromaxillary lymph nodes were collected for further studies of parasitic burden and histopathological analysis. To quantify the number of parasites in the retromaxillary lymph nodes and infected ears the limiting dilution technique was used [21]. Plates were sealed and incubated at 25°C and observed under an inverted microscope every 3 days for up to 30 days to record parasite dilutions. The plate reading result was recorded in the ELIDA 12c software for Windows for the final calculation of the number of parasites present in the samples [22].

Histopathological analysis

For analysis of the histopathological aspects, infected and uninfected ears of each group were removed and fixed in 10% buffered formalin, processed, and stained with hematoxylin-eosin. The changes were analyzed under a standard optical microscope.

Statistical analysis

To verify the statistical significance between the treated groups and the control, the normality test was applied and when there was normal distribution, the t-Student test was used. For comparisons between multiple groups, the one-way ANOVA test was performed, followed by the Bonferroni post-test. The tests were performed using the GraphPad Prism Program version 7.0. In all tests used, the minimum accepted significance was P < 0.05.

Results

Cytotoxic effect of CLF-1 in vitro

Initially, we characterized the effect of J774 macrophages and L. braziliensis promastigotes cultivated in the presence of different concentrations of CLF-1 for 48 hours. Lower CLF-1 concentrations such as 5, 10, and 25 μg/mL were less cytotoxic at levels very similar to the culture medium and drug vehicle (Fig 2A and 2B). CLF-1 presented a significant cytotoxic effect on macrophages only at the highest concentration tested (100 μg/mL) (Fig 2A and 2B). The leishmanicidal effect of CLF-1 on promastigotes was observed in a dose dependent manner (25, 50 and 100 μg/mL) significantly decreasing the number of viable promastigotes compared to medium containing only promastigotes at 24 sustained at 48 hours (Fig 2C and 2D). CLF-1 concentrations of 50 and 100 μg/mL showed no differences in percent promastigote viability compared to amphotericin B at 24 hours (Fig 2A and 2B).

Fig 2.

Fig 2

Open in a new tab

Effect of CLF-1 treatment on cell viability in vitro of J774 macrophages treated with CLF-1 for 24 (A) and 48 (B) hours and Leismania. braziliensis promastigotes for 24 (C) and 48 hours (D). Control: L. braziliensis promastigotes or J774 macrophages without any treatment; DMSO: dimetilsulfoxide; ANF.B: Amphotericin B; Mφ: macrophages. p < 0,0001.

CLF-1 treatment control L. braziliensis infection inside macrophages

The antileishmanial effect of CLF-1 was tested in intracellular amastigotes of L. braziliensis. Interestingly, CLF-1 treatment was able to significantly reduce the number of amastigotes at a lower concentration (10 μg/mL). This effect was not observed at higher CLF-1 concentrations (Fig 3A and 3B).

Fig 3. Effect of CLF-1 treatment on Leishmania braziliensis infected macrophages.

Fig 3

Open in a new tab

(A) Parasite load after treatment with CLF-1 for 24 and (B) 48 hours. L.b.: Leishmania braziliensis infected macrophages; Glu: Glucantime; IFN: Interferon-gamma (p < 0,0001).

Effect of CLF-1 treatment modulate cytokine production by L. braziliensis-infected macrophages

Next, we analyzed the profile of cytokine production by infected macrophages following CLF-1 treatment. IL-12 production was significantly increased following treatment with CLF-1 up to 48 hours (Fig 4A and 4B). A significant production of TNF-α was also detected at 24 hours that decreased at 48 hours. Interestingly, CLF-1 treatment also induced production of anti-inflammatory cytokines, IL-4, and IL-10 at 24 and 48 hours (Fig 4A and 4B).

Fig 4. Production of cytokines in vitro by Leishmania braziliensis infected macrophages treated with CLF-1 for 24 (A) and 48 (B) hours.

Fig 4

Open in a new tab

L. braziliensis infected macrophages were treated with CLF-1 and IL-12, TNF-α, IL-4 and IL-10 production were measured in the supernatant. MØ: macrophages; L.b: Leishmania braziliensis infected macrophages; Glu: Glucantime; p< 0,0001.

CLF-1 treatment of hamsters infected with L. braziliensis induced lesion healing and reduced parasite load

We extended our investigation to in vivo L. braziliensis infection using the hamster model. Overall, topical treatment with CLF-1 was performed for ten consecutive days after the onset of the ulcerated lesion (15 days after infection) resulting in decreased ear thickness that coincided with lesion healing (Fig 5A and 5C). Treatment with glucantime had few animals with ulcerated lesions and were able to reduce lesion thickness earlier but a significant reduction was only observed after treatment conclusion. Although lesions appeared in all animals, it was possible to observe some degree of variation. A significant difference between lesions could be observed at the last day of treatment when CLF-1 and glucantime treated groups recovered faster than the control group that presented lesions that were visually larger and ulcerated (Fig 5B).

Fig 5. Effect of topical CLF-1 treatment in hamsters infected with L. braziliensis.

Fig 5

Open in a new tab

Lesion development in infected hamsters treated for 10 consecutive days with topical CLF-1. (A) Lesion thickness and (B) Representative pictures of lesions from infected ears on the last day of treatment. Parasite load determination in the ear (C) and draining lymph node (D) from hamsters infected with L. braziliensis and treated with CLF-1 dpi = days post infection; ** and * = significance in relation to control. *p < 0,05.

Moreover, animas treated with CLF-1 lesions did not present ulcerated lesions with a necrotic center and there was a significant parasite load reduction at the lesion and lymph node comparing to the group treated with glucantime (Fig 5C and 5D).

Histopathological analysis of infected ears from hamsters treated with CLF-1

The main histopathological finding was the presence of an intense inflammatory exudate with granulomas, especially lesions that still had ulcers on the last day of treatment, regardless of the group observed. The inflammatory infiltrate was mainly composed by macrophages, neutrophils, and lymphocytes (Fig 6B). We observed an extensive presence of apoptotic bodies and small vessels formed in the area closest to the ulcer. The lesion of control animals presented areas of fibrinoid necrosis in addition to an inflammatory exudate composed by infected macrophages. The group treated with antimony presented animals that had non-ulcerated tissue (Fig 6C and 6E). Apoptotic bodies were present with greater intensity and granulomas were present in a more advanced stage in the group treated with CLF-1, indicating a possible control of parasite proliferation (Fig 6F). Treatment with CLF-1 showed a more extensive and more robust re-epithelialization and neovascularization, a hallmark for the healing process (Fig 6D). Therefore, treatment with CLF-1 resulted in an inflammatory response and strong signs of healing with re-epithelialization of the lesion area.

Fig 6. Main histopathological findings of hamsters infected with Leishmania braziliensis and treated with CLF-1.

Fig 6

Open in a new tab

(A) Uninfected ear (200x). (B) Untreated infected ear (200x). (C and E) Infected ear treated with Glucantime (100x and 400x, respectively). (D and F) Infected ear topically treated with CLF-1 (400x). Arrows indicate areas of neovascularization, black circle show an area with a granuloma with activated macrophages.

Discussion

Development of new drugs for CL treatment that are less toxic, more effective and that could be topically or orally administered not requiring outpatient support is critical [23, 24]. L. braziliensis is the major species related to American tegumentary leishmaniasis and treatment is recommended to prevent spread and disfiguring lesions but limited to a few drugs that have very toxic side effects and parasite resistance.

CLF-1 is isolated from Combretum leprosum Mart., a native species that is commonly used as a healing agent to treat skin diseases using plasters to cover wounds with leaves that contain a high concentration of CLF-1 [17]. Previous results demonstrate that CLF-1 presents antileishmanial activity against L. amazonensis in vitro [16]. Here we further explore the anti-leishmanial potential of CLF-1 using the hamster model of L. braziliensis infection employing a topical CLF-1 cream formulation. The use of topical formulations poses advantages such as easy application, with low toxicity and adverse effects, increasing chances of treatment compliance and success. The effectiveness of local therapies has been reported previously. Topical treatment using Arnica tincture showed antileishmanial activity in infected hamsters [25]. A pentamidine cream and a topical miltefosine gel was also tested in L. braziliensis infected mice [26, 27].

Importantly, a CLF-1 topical formulation was previously tested demonstrating a healing effect on skin lesions in rats [17]. Treatment of infected golden hamsters with CLF-1 was performed for ten days topically starting at lesion onset, the time when most patients seek medical treatment. The antileishmanial effect of CLF-1 induced a decrease in parasite load, promoting lesion healing with lesion thickness reduction at the end of treatment. In control mice, dermal lesions were visually larger and histopathological examination showed the presence of an intense inflammatory infiltrate, containing epidermal hyperplasia and ulcerated areas, characteristic of CL lesions. CLF-1 healing effect was also observed in the histopathological analysis of the infected ears, showing reepithelialization and the presence of collagen fibers. Healing coincide with parasite load reduction, both in the lesion and draining lymph node from animals treated with CLF-1.

Cytokine production demonstrated that CLF-1 treatment of infected macrophages significantly increased IL-12 production accompanied by lower production of TNF-α, IL-4 and IL-10, indicating a mixed inflammatory environment. Although IL-12 and TNF-α are key cytokines that activate macrophages and promote Leishmania killing, excessive inflammation is related to the development of more severe clinical manifestations. Thus, the presence of IL-10 and IL-4 is also important, balancing the inflammatory response to prevent tissue damage [6, 28].

Although we have not explored CLF-1 anti-leishmanial mechanism, it was previously reported that CLF-1 is a potential inhibitor of topoisomerase IB [16]. Whether treatment CLF-1 provides an additional effect against other forms of cutaneous leishmaniasis is a question that requires future investigation. Moreover, evaluation of combination therapy, topical CLF-1 and Glucantime, could increase treatment efficacy, lower drug usage, and reduce treatment length and side effects.

Together, the results of this study provide evidence of CLF-1 topical treatment of experimental CL in hamsters is an effective and promising treatment option to the chemotherapies currently available.

Data Availability

Data are available from Zenodo ((DOI: 10.5281/zenodo.8064400).

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Lewnard JA, Jimanus L, Nery N Junior, Machado PR, Glesby MJ, Ko AI, et al. Forecasting temporal dynamics of cutaneous leishmaniasis in northeast Brazil. PLos Neglected Trop Diseas. 2014; 8: e3283. doi: 10.1371/journal.pntd.0003283 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Pearson RD & Sousa AQ. Clinical spectrum of Leishmaniasis. Clin Infect Dis. 1996; 22:1–13. doi: 10.1093/clinids/22.1.1 [DOI] [PubMed] [Google Scholar]
  • 3.Vasconcelos IAB, Vasconcelos AW, Momen H, Grimaldi Jr.G, Alencar JE. Epidemiological studies on American leishmaniasis in Ceará state, Brazil. A. of Trop. Med. & Parasitol. 1988; 82: 547–554. [DOI] [PubMed] [Google Scholar]
  • 4.Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Clinical and mucocutaneous leishmaniasis: Clinical perspectives. J.Am.Dermatol. 2015. 73: 897–908. [DOI] [PubMed] [Google Scholar]
  • 5.Schnorr D, Muniz AC, Passos S, Guimaraes LH, Lago EL, Bacellar O, et al. IFN-γ production to Leishmania antigen supplements the Leishmania skin test in identifying exposure to L. braziliensis infection. Plos Neglect Diseas. 2012; 6: e1947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bacellar O, Lessa H, Schriefer A, Machado P, de Jesus AR, Dutra WO, et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect and Immun. 2002; 70: 6734–40. doi: 10.1128/IAI.70.12.6734-6740.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Salhi A, Rodrigues V, Santoro F, Dessein H, Romano A, Sertorio M, et al. Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J of Immunol. 2008; 180: 6139–6148. [DOI] [PubMed] [Google Scholar]
  • 8.Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nature Reviews Immunol. 2002; 2: 845–858. [DOI] [PubMed] [Google Scholar]
  • 9.Gomes-Silva A, Bittar RC, Nogueira RS, Anato VS, Mattos MS, Oliveira-Neto MP, et al. Can interferon-γ and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection? Clin. And Experim. Immunol. 2007; 149: 440–444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr.Pharm.Des. 2002; 8: 319–42. doi: 10.2174/1381612023396258 [DOI] [PubMed] [Google Scholar]
  • 11.Singh OP, Singh B, Chakravarty J, S Shyam. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect. Dis. Pov. 2016; 8: 19. doi: 10.1186/s40249-016-0112-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Sundar S and Singh A. Recent developments and prospects in the treatment of visceral leishmaniasis. Therap. Advances in Infect. Dis. 2016; 3: 98–109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Croft SLL, Olliaro P. Leishmaniasis chemotherapy–challenges and opportunities. Clinical Microbiol. and Infect. 2011; 17: 1478–1483. doi: 10.1111/j.1469-0691.2011.03630.x [DOI] [PubMed] [Google Scholar]
  • 14.Cheuka PM, Mayoka G, Mutai P, Chibale K. The role of natural products in drug discovery and development against neglected tropical diseases. 2016; 22: 58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Teles CBG, Moreira LS, Silva ADA, Facundo VA, Zuliani J P, Stábeli RG, Silva I. Activity of the lupane isolated from Combretum leprosum against Leishmania amazonensis promastigotes. J of Brazil. Chem, Soc. 2011; 22: 936–942. [Google Scholar]
  • 16.Teles CBG, Moreira-Dill LS, Silva AA, Facundo VA, De Azevedo WF, Da Silva LHP, et al. A lupane-triterpene isolated from Combretum leprosum Mart. fruit extracts that interferes with the intracellular development of Leishmania (L.) amazonensis in vitro. BMC Complem. and Altern. Med. 2015; 15: 165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Nascimento-Neto LG, Evaristo FFV, Alves MFA, Albuquerque MRJR, Santos HS, et al. Effect of the triterpene 3β, 6β, 16β-trihydroxydroxylup-20(29)-ene isolated from leaves of Combretum leprosum Mart. on cutaneous wounds in mice. J. of Ethnopharmacology. 2015; 171: 116–120. [DOI] [PubMed] [Google Scholar]
  • 18.Evaristo FFV, Albuquerque MRJR, Santos HS, Bandeira PN, Ávila FN, Silva BRS, Vasconcelos AA, et al. Antimicrobial effect of the triterpene 3β, 6β, 16β-trihydroxylp-20(29)-ene on planktonic cells and biofilms from gram positive and gram negative bacteria. Biomed Res. Intern. 2014; 2014: 729358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Pinheiro CVG, da Silva WMB, Rodrigues JPV, Rocha YM, Teixeira MJ, de Oliveira RN, de Souza NV, et al. Anti-Leishmania infantum in vitro effect of n-cyclohexyl-1,2,4-xadiazole and its ADME/TOX parameters. J. Parasit. Dis. 2021; 46: 317–322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.De Moura TR, Novais FO, Oliveira LF, Clarêncio J, Noronha A, Barral A, et al. Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis. Infect. Immun. 2005; 73:5827–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Titus RG, Ceredig R, Cerottini JC, Louis JA. Therapeutic effect of anti-L3T4 monoclonal antibody GK 1.5 on cutaneous leishmaniasis in genetically–susceptible BALB/c mice. The J. of Immuno. 1985; 135: 2108–2114. [PubMed] [Google Scholar]
  • 22.Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies III. Validity tests for the single-hit Poisson model. J. Immunol. Meth. 1984; 72: 29–40. [DOI] [PubMed] [Google Scholar]
  • 23.Yardley V, Llanos-Cuentas A, Chappuis F, Doncker SD, Ramirez L, Croft S, Arevalo J, et al. American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility? The J. of Infect. Dis. 2006; 194:1168–1175. doi: 10.1086/507710 [DOI] [PubMed] [Google Scholar]
  • 24.Zauli-Nascimento RC, Miguel DC, Yokoyama-Yasunaka JKU, Pereira LIA, Oliveira MAP, Ribeiro-Dias F, et al. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B. Trop. Med. and Intern. Health. 2010; 15: 68–76. [DOI] [PubMed] [Google Scholar]
  • 25.Robledo SM, Murillo J, Arbeláez N, Montoya A, Ospina V, Jurgens FM et al. Therapeutic efficacy of Arnica in hamsters with Cutaneous Leishmaniasis caused by Leishmania braziliensis and L. tropica. Pharmaceuticals. 2022; 15: 776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Muñoz BY, Mantilla JC, Escobar P. Therapeutic response and safety of the topical, sequential use of antiseptic, keratolytic, and pentamidine creams (3-PACK) on Leishmania (Viannia) braziliensis-infected mice. Mem. Inst Oswaldo Cruz. 2019; 114: e180535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Neira LF, Mantilla JC, Escobar P. Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmamiasis. J Antimicrob Chemother. 2019; 74: 1634–1641. [DOI] [PubMed] [Google Scholar]
  • 28.Ribeiro-de-Jesus A., Almeida R. P., Lessa H., Bacellar O. & Carvalho E. M. Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res. 1998; 31: 143–148. doi: 10.1590/s0100-879x1998000100020 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Manas Ranjan Dikhit

23 Mar 2023

PONE-D-23-02657Leishmanicidal and healing effects of 3β,6β,16β-trihydroxy lup-20 (29)-ene isolated from Combretum leprosum on Leishmania braziliensis infection in vitro and in vivo.PLOS ONE

Dear Dr. Teixeira,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 07 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Manas Ranjan Dikhit

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information on the animal research and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering.

3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this article by Santos et.al, entitled Leishmanicidal and healing……… on Leiahmania braziliensis

infection in vitro and in vivo” the authors have demonstrated anti-leishmanial and wound healing effect

of Combretum leprosum leaves extract. The article has important information and findings but requires

revision with clarification before being accepted for publication.

My comments are below.

1. Brief description of isolation and characterization of CLF-1 in page 5 line 106 should be provided.

2. The cream formulation should be elaborated in page 6 line 135.

3. In figure 1, panel A, B, C & D, the only macrophage bar in all the cases- it is not clear against

which control was these bars normalized. In panel ‘A’ the macrophage bar is around 120 %, in

panel ‘B’ it is around 130%, in ‘C’ it is 110% and in ‘D’ it is less than ‘100’. Please clarify and

correct. It is also unclear why 100µg/ml CFL-1 is toxic to macrophage but not to Leishmania in

that respect.

4. In figure 2 the authors should explain why there is not much effect of duration of treatment.

5. The data provided in the manuscript shows that higher dose of CFL-1 has no effect on number of

amastigotes (Fig 2) but higher dose of CFL-1 do induce the cytokines (Fig 3). How can this be

explained in wound healing and clearance of parasites.

6. I would suggest the authors to measure the parasitic load through some molecular method like

qPCR.

Reviewer #2: Author has shown with different experiments that CLF-1 has in vitro (in J774 macrophage) and in vivo (in Hamster model) anti-leishmanial effect against L. braziliensis. However, author should address the following comments before acceptance.

Comments:

1. Author did not study any mechanism of inhibition for CLF-1 in L. braziliensis as previous study already explored the mechanism of inhibition by CLF-1 in L. amazonensis promastigotes and also showed that CLF-1 has anti-leishmanial activity in-vitro. So, in my opinion the only novel part of this study was to explore the effect of CLF-1 cream in Hamster model. Author should study the mechanism of inhibition in amastigote by isolating the amastigotes from infected macrophages.

2. Author used J774 (mouse cancerous cell line) for in-vitro infection study. In my opinion, author may use mouse peritoneal macrophages for this study as this the primary macrophages.

3. For in-vitro study, author used Amphotericin B as a control and concentration used is 16 µg/ml. What is the rationale behind choosing this concentration? Is there any report?

4. Author has developed CLF-1 cream for topical application. However, author did not provide the details about the process of formulation of the cream.

5. Author has shown that promastigotes viability is reduced with increasing concentration of CLF-1 (Figure 1) and in case of intracellular amastigotes, viability is increased with increasing concentration of CLF-1 (Figure 2). What is the explanation of this contradictory results?

However, I am quite happy with the work but, author need to address the above issues.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Nov 27;18(11):e0287665. doi: 10.1371/journal.pone.0287665.r002

Author response to Decision Letter 0

8 May 2023

ANSWERS TO REVIEWERS:

Reviewer #1: In this article by Santos et al, entitled Leishmanicidal and healing……… on Leishmania braziliensis infection in vitro and in vivo” the authors have demonstrated anti-leishmanial and wound healing effect of Combretum leprosum leaves extract. The article has important information and findings but requires revision with clarification before being accepted for publication.

My comments are below.

1. Brief description of isolation and characterization of CLF-1 in page 5 line 106 should be provided.

More information related to the isolation and characterization of CLF-1 was included in the Material and Methods section as suggested.

2. The cream formulation should be elaborated in page 6 line 135.

A more detailed description of CLF-1 cream formulation was included in the Material and Methods section as suggested.

3. In figure 1, panel A, B, C & D, the only macrophage bar in all the cases- it is not clear against which control was these bars normalized. In panel ‘A’ the macrophage bar is around 120 %, in panel ‘B’ it is around 130%, in ‘C’ it is 110% and in ‘D’ it is less than ‘100’. Please clarify and correct. It is also unclear why 100µg/ml CFL-1 is toxic to macrophage but not to Leishmania in that respect.

We appreciate that the reviewer’s comment and we have corrected figure 1, the bars were normalized based on the experiment controls. While CLF-1 cytotoxicity to macrophages was only observed with the highest concentration (100µg/ml), promastigotes were more susceptible to the toxic effect, observed also with lower CLF-1 concentrations (10 µg/ml). This is probably resulting from different mechanisms of actions of CLF-1 on such distinct cells (macrophages and Leishmania parasites) and should be further explored on future studies.

4. In figure 2 the authors should explain why there is not much effect of duration of treatment.

We believe that we did not observe a significant effect on amastigotes at 24h, but not at 48h, probably due to the kinetics of CLF-1 effect on the intracellular parasites. Unfortunately, we were not able to test in vitro for a longer period. However, the CLF-1 anti-leishmanial effect was evident in vivo on infected hamsters where we observe a clear reduction of parasite numbers and lesions were not ulcerated with a necrotic center compared to the group treated with Glucantime.

5. The data provided in the manuscript shows that higher dose of CFL-1 has no effect on number of amastigotes (Fig 2) but higher dose of CFL-1 do induce the cytokines (Fig 3). How can this be explained in wound healing and clearance of parasites.

The mechanism of CLF-1 treatment on amastigotes (intracellular) and macrophages and the kinetics of the effect observed is probably different and it remains to be elucidated. CLF-1 has been previously described as having an antimicrobial, pro-healing and antiparasitic activities. The wound healing and clearance of parasites is probably resulting, at least in part, by direct modulation of cytokine production that results in parasite killing and promote lesion healing.

6. I would suggest the authors to measure the parasitic load through some molecular method like qPCR.

Although qPCR is a sensitive and specific method, limiting dilution is more accessible, widely used, and a reliable method to quantify live parasites. Thus, we decided to measure the parasite burden using the limiting dilution method to determine the parasite load. This method has been used by our group in other studies (Dutra, et al., 2020 and Freire et al., 2022).

Reviewer #2: Author has shown with different experiments that CLF-1 has in vitro (in J774 macrophage) and in vivo (in Hamster model) anti-leishmanial effect against L. braziliensis. However, author should address the following comments before acceptance.

Comments:

1. Author did not study any mechanism of inhibition for CLF-1 in L. braziliensis as previous study already explored the mechanism of inhibition by CLF-1 in L. amazonensis promastigotes and also showed that CLF-1 has anti-leishmanial activity in-vitro. So, in my opinion the only novel part of this study was to explore the effect of CLF-1 cream in Hamster model. Author should study the mechanism of inhibition in amastigote by isolating the amastigotes from infected macrophages.

The reviewer made an important point about previous work demonstrating the potential protective and healing effect of CLF-1. Infection caused by Leishmania braziliensis and Leishmania amazonensis induce skin lesions, but disease progression and immune evasion mechanisms are distinct reinforcing the importance of testing CLF-1 against each individual Leishmania species. Investigation of the mechanism of action of CLF-1 treatment on amastigotes and macrophages are the subject of a future study.

2. Author used J774 (mouse cancerous cell line) for in-vitro infection study. In my opinion, author may use mouse peritoneal macrophages for this study as this the primary macrophages.

Although we have not used a primary culture of macrophages due to a limitation on the number of experimental hamsters/mice available at the time, we believe that J774 cells, that are widely used for in vitro tests, also provide reliable and representative results.

3. For in-vitro study, author used Amphotericin B as a control and concentration used is 16 µg/ml. What is the rationale behind choosing this concentration? Is there any report?

We have used this concentration of Amphotericin B as a control for parasite killing. It was based on previous work published by the group (Pinheiro et al., 2021). This reference was included in the Material and Methods.

4. Author has developed CLF-1 cream for topical application. However, author did not provide the details about the process of formulation of the cream.

Details concerning the formulation of CLF-1 cream were included in the Material and Methods section as suggested.

5. Author has shown that promastigotes viability is reduced with increasing concentration of CLF-1 (Figure 1) and in case of intracellular amastigotes, viability is increased with increasing concentration of CLF-1 (Figure 2). What is the explanation of this contradictory results? However, I am quite happy with the work but, author need to address the above issues.

We observed a different effect on promastigotes and amastigotes probably as a result of the mechanism of action and kinetics of CLF-1 on the different stages (intracellular x extracellular). Unfortunately, we were not able to test in vitro for a longer period as we moved forward for in vivo experiments. The CLF-1 anti-leishmanial effect was evident in vivo on infected hamsters where we observe a clear reduction of parasite and lesions were not ulcerated with a necrotic center compared to the group treated with Glucantime.

Attachment

Submitted filename: ResponsetoReviewers.docx

Click here for additional data file. (21KB, docx)

Decision Letter 1

Manas Ranjan Dikhit

12 Jun 2023

Leishmanicidal and healing effects of 3β,6β,16β-trihydroxy lup-20 (29)-ene isolated from Combretum leprosum on Leishmania braziliensis infection in vitro and in vivo.

PONE-D-23-02657R1

Dear Dr. Maria,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Manas Ranjan Dikhit

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

Acceptance letter

Manas Ranjan Dikhit

10 Jul 2023

PONE-D-23-02657R1

Leishmanicidal and healing effects of 3β,6β,16β-trihydroxy lup-20 (29)-ene isolated from Combretum leprosum on Leishmania braziliensis infection in vitro and in vivo

Dear Dr. Teixeira:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Manas Ranjan Dikhit

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: ResponsetoReviewers.docx

    Click here for additional data file. (21KB, docx)

    Data Availability Statement

    Data are available from Zenodo ((DOI: 10.5281/zenodo.8064400).

    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES